Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Chemical Works of Gedeon Richter's Net Cash per Share or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Cash Ratio of Chemical Works of Gedeon Richter was 20111.11. The lowest was 46.70. And the median was 117.58.
RGEDF's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.66 * Ranked among companies with meaningful Price-to-Net-Cash only.
Chemical Works of Gedeon Richter (OTCPK:RGEDF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Chemical Works of Gedeon Richter Net Cash per Share Related Terms
Chemical Works of Gedeon Richter Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter Net Cash per Share Chart
RGEDF vs ZTS, UTHR, VTRS: Net Cash per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Chemical Works of Gedeon Richter's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemical Works of Gedeon Richter Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chemical Works of Gedeon Richter's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Chemical Works of Gedeon Richter's Price-to-Net-Cash falls into.
Chemical Works of Gedeon Richter Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter (RGEDF) has a Net Cash per Share of $-0.81 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Chemical Works of Gedeon Richter and its competitors. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #999999 out of 253 companies in the Drug Manufacturers industry.
Is Chemical Works of Gedeon Richter's Net Cash per Share too high?
Chemical Works of Gedeon Richter's current Net Cash per Share is $-0.81. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #999999 out of 253 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's Net Cash per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #999999 out of 253 companies for Net Cash per Share. This places Chemical Works of Gedeon Richter in the lower half of its industry. The industry median Net Cash per Share is 8.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 8.66, based on 253 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Chemical Works of Gedeon Richter and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 8.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemical Works of Gedeon Richter's current Net Cash per Share is $-0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (RGEDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $35.26, compared to a current price of $43.25 — trading 22.7% above its estimated fair value. The current Net Cash per Share is $-0.81. Chemical Works of Gedeon Richter's overall GF Score™ is 94/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (RGEDF), the current Net Cash per Share is $-0.81 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemical Works of Gedeon Richter (RGEDF) Overvalued in 2026?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued.
The current stock price of $43.25 is trading 22.7% above its estimated GF Value™ of $35.26.
GuruFocus considers Chemical Works of Gedeon Richter to be Modestly Overvalued.
Key valuation signals for RGEDF:
Net Cash per Share: $-0.81
GF Value™: $35.26 vs. price of $43.25 (22.7% above fair value)
No single metric tells the full story. See the RGEDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
94GF Score
Get the complete analysis for RGEDF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEDF has been successfully added to your 
